About Novo Nordisk
Novo Nordisk is a company based in Bags Sword (Denmark) founded in 1923. It operates as a Direct-to-Consumer (D2C) and Professional Services. Novo Nordisk has raised $145 thousand across 9 funding rounds from investors including European Union and IFU. The company has 76,300 employees as of December 31, 2024. Novo Nordisk has completed 13 acquisitions, including Akero Therapeutics, Biocorp and Calibrium. Novo Nordisk offers products and services including Ozempic, Wegovy, and Cagrilintide. Novo Nordisk operates in a competitive market with competitors including Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
- Headquarter Bags Sword, Denmark
- Employees 76300 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Novo Nordisk A/S Class B
-
Annual Revenue
$40.45 B (USD)25.03as on Dec 31, 2024
-
Net Profit
$14.07 B (USD)20.68as on Dec 31, 2024
-
EBITDA
$20.61 B (USD)32.83as on Dec 31, 2024
-
Total Equity Funding
$145 K (USD)
in 9 rounds
-
Latest Funding Round
$173.74 K (USD), Grant
Mar 01, 2022
-
Investors
European Union
& 1 more
-
Employee Count
76300
as on Dec 31, 2024
-
Investments & Acquisitions
Akero Therapeutics
& 12 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Novo Nordisk
Novo Nordisk is a publicly listed company on the OMXCOP with ticker symbol NOVO_B in Denmark, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Novo Nordisk
Novo Nordisk offers a comprehensive portfolio of products and services, including Ozempic, Wegovy, and Cagrilintide.
Ozempic is used for reducing cardiovascular risks effectively.
Wegovy is prescribed for weight loss management purposes.
Cagrilintide is developed for advanced obesity treatment solutions.
People of Novo Nordisk
Unlock access to complete
Unlock access to complete
Leadership Team
275 people
Software Development Team
233 people
Senior Team
108 people
Product Management Team
58 people
Finance and Accounting
53 people
Human Resources and Administration
53 people
Operations Team
44 people
Data Analysis and Operations Team
42 people
Unlock access to complete
Funding Insights of Novo Nordisk
Novo Nordisk has successfully raised a total of $145K across 9 strategic funding rounds. The most recent funding activity was a Grant round of $173.74 thousand completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Novo Nordisk
Novo Nordisk has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union and IFU.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investment firm
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Novo Nordisk
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Novo Nordisk
Novo Nordisk has strategically engaged in corporate development activities, having acquired 13 companies. Notable acquisitions include Akero Therapeutics, Biocorp and Calibrium.
Investment portfolio details for Novo Nordisk
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Small molecule therapeutics for metabolic disorders are developed.
|
Locked | Locked | 2017 | Locked | |
|
Novel therapeutics for metabolic diseases and obesity are developed.
|
Locked | Locked | 2017 | Locked | |
|
Non-coding RNA therapeutics are developed for cardiovascular disease treatment.
|
Locked | Locked | 2016 | Locked |
Complete acquisition details for Novo Nordisk
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Novo Nordisk
Detailed financials for Novo Nordisk
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Novo Nordisk Comparisons
Peer comparison for Novo Nordisk
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Novo Nordisk
Novo Nordisk operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of multiple disorders
|
Detailed competitors of Novo Nordisk
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Novo Nordisk
Complete news archive for Novo Nordisk
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Novo Nordisk
Novo Nordisk was founded in 1923 and raised its 1st funding round 61 years after it was founded.
Novo Nordisk is headquartered in Bags Sword, Denmark.
Lars Fruergaard Jorgensen is the current CEO of Novo Nordisk.
Novo Nordisk is a funded company, having raised a total of $145K across 9 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Novo Nordisk is 76,300.
Annual revenue of Novo Nordisk is $40.45B as on Dec 31, 2024.
Novo Nordisk is focused on the development and distribution of pharmaceutical products targeting chronic conditions such as diabetes and obesity. Solutions are provided in various therapeutic areas with an emphasis on innovative treatments. The company operates within the healthcare sector, prioritizing science and technology to address unmet medical needs. Sustainable business practices are integrated into operations, alongside partnerships and a commitment to responsible sourcing. Global procurement strategies are employed to ensure quality and efficiency in supply chains.
Novo Nordisk's top competitors include Merck, Roivant Sciences and AbbVie.
Novo Nordisk offers Ozempic, Wegovy, and Cagrilintide.
Yes, Novo Nordisk is publicly traded on OMXCOP under the ticker symbol NOVO_B.
Novo Nordisk has made 13 acquisitions, including Akero Therapeutics, Biocorp, and Calibrium.
Novo Nordisk has 2 investors. Key investors include European Union, and IFU.
The ticker symbol of Novo Nordisk is NOVO_B on OMXCOP.